Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024)
Spyre Therapeutics' (SYRE) quarterly Preferred Stock Liabilities came in at $253.4 million in Q1 2024, up 199.69% on a QoQ basis from $84.6 million in Q4 2023.
Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024) Analysis & Trends
Spyre Therapeutics (SYRE) has 4 years of Preferred Stock Liabilities data on file, last reported at $253.4 million in Q1 2024.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $253.4 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $253.4 million (changed N/A YoY) and the FY2023 annual result came in at $84.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $253.4 million in Q1 2024, from $84.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $387.1 million in Q3 2023 to a low of $84.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 253.41 Mn |
| Dec 31, 2023 | 84.56 Mn |
| Sep 30, 2023 | 387.11 Mn |
| Jun 30, 2023 | 197.32 Mn |
| Mar 31, 2016 | 44.74 Mn |
| Dec 31, 2015 | 13.57 Mn |